

CERTIFICATE OF ANALYSIS

* FOR QUALITY ASSURANCE PURPOSES. NOT A MAINE COMPLIANCE CERTIFICATE.

LOF516C (FLOWER) // PRODUCED: DEC 27, 2024

CLIENT: BLOSSOM MED // BATCH: PASS



MATRIX: FLOWER ¹
SAMPLE ID: NAL-241220-016
COLLECTED ON: DEC 20, 2024
RECEIVED ON: DEC 20, 2024
BATCH SIZE: 2.8 G ¹
SAMPLE SIZE: 2.8 G ¹

SAMPLED BY: SCOTT WEENE RECEIVED BY: ZOE COLWELL

1 ENTERED BY CLIENT

CANNABINOID OVERVIEW	
CBDA:	14.1 %
CBD:	3.44 %
TOTAL CANNABINOIDS:	19.2 %

BATCH RESULT: PASS

POTENCY

TESTED

CAN.1: POTENCY & CANNABINOID PROFILE BY HPLC-UV PREPARATION: DEC 26, 2024 // ANALYSIS: DEC 26, 2024

ANALYTE	LIMIT	AMT	AMT	LOD/LOQ (%)	PASS/FAIL
СВС		0.267 %	2.67 mg/g	0.0685/0.137	N/A
CBCA		0.610 %	6.10 mg/g	0.0685/0.137	N/A
CBD		3.44 %	34.4 mg/g	0.0685/0.137	N/A
CBDA		14.1 %	141 mg/g	0.0685/0.137	N/A
CBDV		ND	ND	0.0685/0.137	N/A
CBDVA		< LOQ	< LOQ	0.0685/0.137	N/A
CBG		ND	ND	0.0685/0.137	N/A
CBGA		0.222 %	2.22 mg/g	0.0685/0.137	N/A
CBL		ND	ND	0.137/0.137	N/A
CBLA		ND	ND	0.0685/0.137	N/A
CBN		ND	ND	0.0685/0.137	N/A

ANALYTE	LIMIT	AMT	AMT	LOD/LOQ (%)	PASS/FAIL
CBNA		ND	ND	0.0685/0.137	N/A
Δ ⁸ -THC		ND	ND	0.137/0.137	N/A
Δ8-THCA		ND	ND	0.137/0.137	N/A
Δ ⁹ -THC		0.261 %	2.61 mg/g	0.0685/0.137	N/A
Δ ¹⁰ -THC		ND	ND	0.0685/0.137	N/A
EXO-THC		ND	ND	0.137/0.137	N/A
THCA		0.322 %	3.22 mg/g	0.137/0.137	N/A
THCV		ND	ND	0.0685/0.137	N/A
THCVA		ND	ND	0.0685/0.137	N/A
TOTAL THC**		0.543 %	5.43 mg/g		N/A
TOTAL CBD**		15.8 %	158 mg/g		N/A

** TOTAL THC = (THCA X 0.877) + DELTA-9-THC

** TOTAL CBD = (CBDA X 0.877) + CBD

Reported on an as received basis

 $1000 \mu g/g = 1 mg/g$



AUTHORIZED BY:

DEVIN DUTRISAC

SCIENTIST II, NOVA ANALYTIC LABS

DEC 27, 2024

NOTES

DEVIN DUTRISAC DEC 27, 2024 POTENCY & CANNABINOID PROFILE BY HPLC-UV

THE STANDARD LAB UNCERTAINTY FOR POTENCY IS 5% OF THE REPORTED VALUE.

ALL TESTS WERE PERFORMED IN ACCORDANCE WITH THE RULES AND REGULATIONS SET FORTH IN THE MAINE ADULT USE PROGRAM. LABORATORY SAMPLING PROTOCOLS ARE GOVERNED BY THE OCP'S SAMPLING GUIDANCE DOCUMENTS. ALL INFORMATION PROVIDED BY THE CLIENT, INCLUDING SELF SAMPLING, MUST BE ACCURATE AND ADHERE TO THE SAME RULES AND REGULATIONS. HOWEVER, CLIENT PROVIDED INFORMATION, INCLUDING SAMPLING, IS ULTIMATELY THE RESPONSIBILITY OF THE PROVIDING LICENSEE, REGISTERED CAREGIVER, PATIENT OR THE LIKE AND FAILURE TO FOLLOW SAID PROTOCOLS COULD LEAD TO ERRONEOUS TEST RESULTS. NOTEL POTENTIAL AND/OR EXISTING HAZARDS WERE ANALYZED. THIS CERTIFICATE OF ANALYSIS IS RELEVANT ONLY TO THOSE ITEMS TESTED. THE SAMPLE WAS PROVIDED TO THE LABORATORY FOR TESTING BY THE CLIENT AND THE SAMPLE WAS TESTED AS RECEIVED.

END OF REPORT



